在人工智能时代,评估毒理学研究中的偏差风险
Thomas Hartung1,2,3, Sebastian Hoffmann4,5, Paul Whaley4,6
1CAAT-Europe, University of Konstanz, Constance, Germany. thartun1@jhu.edu.
Archives of toxicology
|July 4, 2025
概括
人工智能 (AI) 可以自动化毒理学研究中的偏差评估风险,提高效率和准确性. 然而,人工智能模型需要仔细验证,以解决它们对可靠的基于证据的决策方面的偏见.
科学领域:
- 毒理学 毒理学 毒理学
- 人工智能的人工智能
- 生物医学信息学 生物医学信息学
背景情况:
- 偏差风险对毒理学研究的可靠性和证据综合产生了重大影响.
- 传统的偏见评估方法是主观的,耗时的.
- 人工智能的进步为自动偏见检测和评估提供了潜力.
研究的目的:
- 审查毒理学研究中的关键偏差 (体内,体外,内).
- 讨论现有的偏见评估工具 (例如,SYRCLE,OHAT).
- 探索AI在偏见评估风险中的整合和挑战.
主要方法:
- 在毒理学研究中偏见的文献综述.
- 对用于偏差检测的AI应用进行讨论.
- 对AI模型易受算法和数据偏差的分析.
主要成果:
- 人工智能集成提高了偏见评估的效率,一致性和准确性.
- 由于固有的偏见,人工智能模型需要强大的验证和透明度.
- 标准化的人工智能支持的方法对于减轻人工智能驱动分析中的偏见至关重要.
结论:
- 人工智能为改善毒理学证据质量和可靠性提供了巨大的潜力.
- 解决人工智能的算法和数据偏差对于可靠的结果至关重要.
- 促进合作和开发抗偏见的AI模型是未来进步的关键.
关键词:
人工智能有偏见的偏见人工智能的人工智能是人工智能.基于证据的毒理学这就是OHATAT.监管毒理学 监管毒理学偏见的风险 偏见的风险这就是SYRCLE.系统性审查 系统性审查这是一个 ToxRTool 工具.毒理学 毒理学 毒理学更多相关视频
05:47In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox
Published on: August 28, 2019
14.1K
16:02Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation
Published on: February 10, 2023
2.8K
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
180
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
180
01:25Mutagenicity and Carcinogenicity
1.4K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.4K